Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors

被引：2
|
作者：
Lin, C-C. [1 ]
Grewal, J. [2 ]
Baranda, J. C. [3 ]
Schneider, R. E. [4 ]
Zhang, J. [5 ]
Bai, L-Y. [6 ]
Yeh, Y-M. [7 ]
Sommerhalder, D. [8 ]
Li, G. [9 ]
Shen, L. [10 ]
Hsu, H-C. [11 ]
Alese, O. [12 ]
Yin, R. [13 ]
Hsieh, C-Y. [14 ]
Cai, S. X. [15 ]
Tian, Y. E. [16 ]
Xia, H. [14 ]
Li, B. [14 ]
Zhang, M. [14 ]
Zhang, C. [14 ]
机构：
[1] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Norton Canc Inst, Med Oncol, Louisville, KY USA
[3] Univ Kansas, Clin Res Ctr, Med Oncol Dept, Kansas City, KS USA
[4] Mary Crowley Canc Res Ctr, Outpatient Evaluat & Treatment Ctr Texas Oncol, Dallas, TX USA
[5] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China
[6] China Med Univ Hosp, Div Hematol & Oncol, New Taipei, Taiwan
[7] NCKUH Natl Cheng Kung Univ Hosp, Oncol, Tainan, Taiwan
[8] NEXT Oncol, Oncol, San Antonio, TX USA
[9] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Gynaecol Oncol, Wuhan, Peoples R China
[10] Beijing Canc Hosp, Dept Digest Oncol, Beijing, Peoples R China
[11] Linkou Chang Gung Mem Hosp, Chang Gung Med Fdn, Oncol, Taoyuan, Taiwan
[12] Emory Univ Hosp, Hematol & Med Oncol, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[13] Sichuan Univ, West China Womens & Childrens Hosp, West China Univ Hosp 2, Dept Oncol & Chemoradiotherapy, Chengdu, Peoples R China
[14] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China
[15] IMPACT Therapeut Inc Shanghai, Dev, Shanghai, Peoples R China
[16] IMPACT Therapeut Inc Shanghai, Res, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1848
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
662MO
引用
收藏
页码：S466 / S466
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.
    Im, Seock-Ah
    Lee, SeungHwan
    Lee, Keun Wook
    Lee, Youngjoo
    Sohn, Joohyuk
    Kim, Jee Hyun
    Im, Young-Hyuck
    Park, Kyong Hwa
    Oh, Do-Youn
    Kim, Min Hwan
    Park, Yeon Hee
    Kim, Tae Min
    Choi, Yoon Ji
    Lee, Chang-Seok
    Park, Jiseon
    Baek, Nam Seok
    Choi, MiKyung
    Kim, John
    Yu, Eunyoung
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
    Hong, David S.
    Kurzrock, Razelle
    Wheler, Jennifer J.
    Naing, Aung
    Falchook, Gerald S.
    Fu, Siqing
    Kim, Kevin B.
    Davies, Michael A.
    Nguyen, Ly M.
    George, Goldy C.
    Xu, Lucy
    Shumaker, Robert
    Ren, Min
    Mink, Jennifer
    Bedell, Cynthia
    Andresen, Corina
    Sachdev, Pallavi
    O'Brien, James P.
    Nemunaitis, John
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4801 - 4810
  • [33] Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors
    Borad, M. J.
    Akerele, C. E.
    Ramanathan, R. K.
    Northfelt, D. W.
    Reyderman, L.
    Verbel, D.
    Feit, K.
    Von Hoff, D. D.
    Tibes, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [37] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
    Shapiro, Geoffrey I.
    Do, Khanh T.
    Tolaney, Sara M.
    Hilton, John F.
    Cleary, James M.
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Cai, Dongpo
    Downey, Elizabeth
    Pruitt-Thompson, Solida
    Barry, Suzanne M.
    Kochupurakkal, Bose
    Geradts, Joseph
    Unitt, Christine
    D'Andrea, Alan D.
    Muzikansky, Alona
    Piekarz, Richard
    Doyle, L. Austin
    Supko, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [38] A phase 1, multi-center, open-label, dose-escalation and dose expansion study of CBP-1018, a bi-ligand-drug conjugate, in patients with heavily treated advanced solid tumors
    Li, Kaiwen
    Wu, Junyan
    Ye, Suiwen
    Liu, Yanqiong
    Huang, Hao
    Fan, Fan
    Lai, Yiming
    Zhuang, Suili
    Zhou, Liyan
    Huang, Robert
    Teng, Yan
    Chai, Xiaoyan
    Shi, Yehui
    Huang, Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
    de Braud, F.
    Cascinu, S.
    Spitaleri, G.
    Pilz, K.
    Clementi, L.
    Liu, D.
    Sikken, P.
    De Pas, T.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2341 - 2346
  • [40] Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors.
    Tolcher, Anthony
    Mamdani, Hirva
    Chalasani, Pavani
    Meric-Bernstam, Funda
    Gazdoiu, Mihaela
    Makris, Lukas
    Pultar, Philippe
    Voliotis, Dimitris
    CANCER RESEARCH, 2021, 81 (13)
12345